<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92655</article-id><article-id pub-id-type="doi">10.7554/eLife.92655</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-336899"><name><surname>Bergamini</surname><given-names>Marco</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6161-707X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-336900"><name><surname>Dalla Volta</surname><given-names>Alberto</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8009-7663</contrib-id><email>alberto.dallavolta@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337060"><name><surname>Palumbo</surname><given-names>Carlotta</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337061"><name><surname>Zamboni</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337062"><name><surname>Triggiani</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336904"><name><surname>Zamparini</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336905"><name><surname>Laganà</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336906"><name><surname>Rinaudo</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-337063"><name><surname>Di Meo</surname><given-names>Nunzia</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337064"><name><surname>Caramella</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337065"><name><surname>Bresciani</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337066"><name><surname>Valcamonico</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337067"><name><surname>Borghetti</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337068"><name><surname>Guerini</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240680"><name><surname>Farina</surname><given-names>Davide</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4075-0001</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337070"><name><surname>Antonelli</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-337071"><name><surname>Simeone</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-299984"><name><surname>Mazziotti</surname><given-names>Gherardo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5458-701X</contrib-id><email>gherardo.mazziotti@hunimed.eu</email><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257919"><name><surname>Berruti</surname><given-names>Alfredo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02q2d2610</institution-id><institution>Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia</institution></institution-wrap><addr-line><named-content content-type="city">Brescia</named-content></addr-line><country>Italy</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02gp92p70</institution-id><institution>Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore Della Carità Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Novara</named-content></addr-line><country>Italy</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02q2d2610</institution-id><institution>Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia</institution></institution-wrap><addr-line><named-content content-type="city">Brescia</named-content></addr-line><country>Italy</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02q2d2610</institution-id><institution>Radiation Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia</institution></institution-wrap><addr-line><named-content content-type="city">Brescia</named-content></addr-line><country>Italy</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04kevy945</institution-id><institution>Tecnologie Avanzate S.r.l</institution></institution-wrap><addr-line><named-content content-type="city">Turin</named-content></addr-line><country>Italy</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02q2d2610</institution-id><institution>Radiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia</institution></institution-wrap><addr-line><named-content content-type="city">Brescia</named-content></addr-line><country>Italy</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02q2d2610</institution-id><institution>Division of Biotechnology, Department of Molecular and Translational Medicine (DMTM), University of Brescia</institution></institution-wrap><addr-line><named-content content-type="city">Brescia</named-content></addr-line><country>Italy</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00sm8k518</institution-id><institution>Urology Unit, AOUI Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona</institution></institution-wrap><addr-line><named-content content-type="city">Verona</named-content></addr-line><country>Italy</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/020dggs04</institution-id><institution>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan</institution></institution-wrap><addr-line><named-content content-type="city">Milan</named-content></addr-line><country>Italy</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05d538656</institution-id><institution>Endocrinology, Diabetology and Medical Andrology Unit, Metabolic Bone Diseases and Osteoporosis Section, IRCCS Humanitas Research Hospital,</institution></institution-wrap><addr-line><named-content content-type="city">Milan</named-content></addr-line><country>Italy</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kim</surname><given-names>Se-Min</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Harper</surname><given-names>Diane M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan-Ann Arbor</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>04</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e92655</elocation-id><history><date date-type="received" iso-8601-date="2023-09-10"><day>10</day><month>09</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-04-03"><day>03</day><month>04</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2023-10-25"><day>25</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.24.23297490"/></event></pub-history><permissions><copyright-statement>© 2024, Bergamini et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Bergamini et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92655-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92655-figures-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Among its extragonadal effects, follicle-stimulating hormone (FSH) has an impact on body composition and bone metabolism. Since androgen deprivation therapy (ADT) has a profound impact on circulating FSH concentrations, this hormone could potentially be implicated in the changes of fat body mass (FBM), lean body mass (LBM), and bone fragility induced by ADT. The objective of this study is to correlate FSH serum levels with body composition parameters, bone mineral density (BMD), and bone turnover markers at baseline conditions and after 12 months of ADT.</p></sec><sec id="abs2"><title>Methods:</title><p>Twenty-nine consecutive non-metastatic prostate cancer (PC) patients were enrolled from 2017 to 2019 in a phase IV study. All patients underwent administration of the luteinizing hormone-releasing hormone antagonist degarelix. FBM, LBM, and BMD were evaluated by dual-energy x-ray absorptiometry at baseline and after 12 months of ADT. FSH, alkaline phosphatase, and C-terminal telopeptide of type I collagen were assessed at baseline and after 6 and 12 months. For outcome measurements and statistical analysis, <italic>t</italic>-test or sign test and Pearson or Spearman tests for continuous variables were used when indicated.</p></sec><sec id="abs3"><title>Results:</title><p>At baseline conditions, a weak, non-significant, direct relationship was found between FSH serum levels and FBM at arms (<italic>r</italic> = 0.36) and legs (<italic>r</italic> = 0.33). Conversely, a stronger correlation was observed between FSH and total FBM (<italic>r</italic> = 0.52, p = 0.006), fat mass at arms (<italic>r</italic> = 0.54, p = 0.004), and fat mass at trunk (<italic>r</italic> = 0.45, p = 0.018) assessed after 12 months. On the other hand, an inverse relationship between serum FSH and appendicular lean mass index/FBM ratio was observed (<italic>r</italic> = −0.64, p = 0.001). This is an ancillary study of a prospective trial and this is the main limitation.</p></sec><sec id="abs4"><title>Conclusions:</title><p>FSH serum levels after ADT could have an impact on body composition, in particular on FBM. Therefore, FSH could be a promising marker to monitor the risk of sarcopenic obesity and to guide the clinicians in the tailored evaluation of body composition in PC patients undergoing ADT.</p></sec><sec id="abs5"><title>Funding:</title><p>This research was partially funded by Ferring Pharmaceuticals. The funder had no role in design and conduct of the study, collection, management, analysis, and interpretation of the data and in preparation, review, or approval of the manuscript.</p></sec><sec id="abs6"><title>Clinical trial number:</title><p>clinicalTrials.gov <related-object id="RO1" source-type="clinical-trials-registry" source-id="ClinicalTrials.gov" source-id-type="registry-name" document-id="NCT03202381" document-id-type="clinical-trial-number" xlink:href="https://clinicaltrials.gov/show/NCT03202381">NCT03202381</related-object>, EudraCT Number 2016-004210-10.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Treatments given to cancer patients can cause negative side effects. For example, a treatment known as androgen deprivation therapy – which is used to reduce male sex hormone levels in prostate cancer patients – can lead to increased body fat percentage and decreased bone density. These adverse effects can have further negative impacts on patient health, such as increasing the risk of cardiovascular disease and fractures from falls from standing height or less, respectively. Understanding how androgen deprivation therapy contributes to these negative side effects may help clinicians better manage care and outcomes for patients with prostate cancer.</p><p>Follicle stimulating hormone (or FSH for short) has roles in male and female reproduction but has also been linked to changes in body composition. For example, elevated FSH levels are associated with higher total fat body mass in post-menopausal women. While androgen deprivation therapy is known to alter FSH blood levels, the impact of this change in prostate cancer patients was not well understood.</p><p>To investigate the effect of androgen deprivation therapy on FSH levels and body composition, Bergamini et al. used X-ray technology to measure total fat body mass in prostate cancer patients before and after undergoing 12 months of androgen deprivation therapy. The findings showed that patient FSH blood levels significantly decreased after 12 months of treatment. Higher FSH blood levels strongly correlated with increased total fat body mass after 12 months of treatment.</p><p>The findings of this clinical trial suggest that FSH blood levels impact the body composition of patients undergoing androgen deprivation therapy. As a result, FSH blood levels may be a suitable biomarker for identifying patients that are more likely to develop obesity and are therefore at greater risk of complications such as cardiovascular disease.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>prostate cancer</kwd><kwd>androgen deprivation</kwd><kwd>FSH</kwd><kwd>body composition</kwd><kwd>bone</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003122</institution-id><institution>Ferring</institution></institution-wrap></funding-source><award-id>..</award-id><principal-award-recipient><name><surname>Berruti</surname><given-names>Alfredo</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Follicle-stimulating hormone in the reference range influences body composition in men exposed to hormone-deprivation therapy for prostate cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Recent preclinical and clinical studies have shown that follicle-stimulating hormone (FSH) exerts effects beyond those on gonadal tissue, which have been known for a long time (<xref ref-type="bibr" rid="bib11">Lizneva et al., 2019</xref>). In the animal model, FSH has been observed to stimulate osteoclastic activity and therefore to exert a negative role on bone mass (<xref ref-type="bibr" rid="bib24">Sun et al., 2006</xref>; <xref ref-type="bibr" rid="bib29">Zaidi et al., 2023</xref>; <xref ref-type="bibr" rid="bib6">Gera et al., 2022</xref>). Furthermore, FSH was found to have a positive action on adipocytes and the blockade of FSH induced by antibodies against FSH receptor caused an increase in bone mass and a reduction of body fat (<xref ref-type="bibr" rid="bib10">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Rojekar et al., 2023</xref>). These preclinical data were confirmed in clinical studies. Large epidemiologic data have shown significant reductions in bone mineral density (BMD) and high resorption rates 2–3 years prior to menopause, when FSH serum levels are increasing, which is also associated with increased body weight and visceral adiposity (<xref ref-type="bibr" rid="bib25">Thurston et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">Senapati et al., 2014</xref>). A longitudinal study involving post-menopausal women has shown that increases in circulating FSH levels were associated with greater increases in the percentage of total body fat, total body fat mass, and subcutaneous adipose tissue (<xref ref-type="bibr" rid="bib13">Mattick et al., 2022</xref>). Moreover, clinical studies have found that FSH is also involved in the modulation of lean mass. A large cohort study of perimenopausal women showed that increased FSH concentrations were associated with increasing fat mass and decreasing lean mass measured by bioelectrical impedance analysis (<xref ref-type="bibr" rid="bib23">Sowers et al., 2007</xref>). Another recent prospective study showed that the indicators of sarcopenia were strongly associated with gonadotropins levels, especially in older men (<xref ref-type="bibr" rid="bib7">Guligowska et al., 2021</xref>). The impact of FSH on body composition may at least partially explain the observed correlation between FSH levels and the risk of cardiovascular events (<xref ref-type="bibr" rid="bib16">Munir et al., 2012</xref>; <xref ref-type="bibr" rid="bib22">Silva et al., 2013</xref>; <xref ref-type="bibr" rid="bib5">El Khoudary et al., 2016</xref>).</p><p>Studies clarifying the relationship among FSH, body composition measures, and BMD in prostate cancer (PC) patients are lacking. Likewise, the interaction between the variation of FSH serum levels and the modification of these parameters in PC patients undergoing androgen deprivation therapy (ADT) is not known.</p><p>We recently conducted the BLADE study (Bone mineraL mAss Dexa dEgarelix), a prospective phase IV study designed to obtain explorative information on dual-energy x-ray absorptiometry (DXA) measurement changes in lean body mass (LBM) and fat body mass (FBM) in patients with non-metastatic PC treated with degarelix, an LHRH (luteinizing hormone-releasing hormone) antagonist that has been developed to achieve effective long-term medical castration without the risk of testosterone surge and its associated flare. Data on changes in total LBM and FBM and on the impact of degarelix on BMD and bone turnover markers were recently published (<xref ref-type="bibr" rid="bib17">Palumbo et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Palumbo et al., 2022</xref>).</p><p>Here, we analyse the association of FSH with DXA-assessed FBM, LBM, and BMD and bone turnover markers at baseline and after degarelix administration in the patients enrolled in the BLADE study.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Trial design and endpoints</title><p>BLADE is a single-centre, prospective, interventional phase IV study (clinicalTrials.gov NCT03202381, EudraCT Number 2016-004210-10) conducted at the Prostate Cancer Unit of the Azienda Socio Sanitaria Territoriale degli Spedali Civili and Università degli Studi of Brescia. The study was carried out in accordance with the Declaration of Helsinki Principles and Good Clinical Practices and was approved by the Ethics Committee of Brescia (approval number NP2540). All patients provided a written informed consent. Male patients with histologically confirmed PC without bone metastasis at bone scintigraphy, judged eligible to ADT according to current guidelines recommendations (<xref ref-type="bibr" rid="bib3">Cornford et al., 2017</xref>; <xref ref-type="bibr" rid="bib15">Mottet et al., 2017</xref>) after a multidisciplinary discussion, were enrolled (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Eligibility criteria have been published elsewhere (<xref ref-type="bibr" rid="bib17">Palumbo et al., 2021</xref>). Degarelix was administered as a subcutaneous injection with a starting dose of 240 mg, followed by a maintenance dose of 80 mg every 28 days. After 12 months, treatment with degarelix was continued as clinically indicated. DXA measurements for assessing BMD and body composition parameters were performed at baseline and after 12 months, using Hologic QDR-4500W instrumentation (Hologic Corporation, Waltham, Massachusetts).</p></sec><sec id="s2-2"><title>Assessment of regional LBM and FBM by dual x-ray absorptiometry</title><p>DXA measurements related to whole body DXA scans were extracted from Apex Software version 3.4.</p><p>The densitometric image of each patient was divided, following the manufacturer’s instructions, into different body districts, including arms, legs, trunk, head, and other derived regions, such as the android and gynoid zone.</p><p>BMD, bone mineral content (BMC), fat free mass, and fat mass were assessed for every region of interest, where fat free mass was provided by the software in terms of lean soft tissue plus BMC. Despite the lean mass measured by DXA counts also skin, connective tissue, and some lean components within the adipose tissue (<xref ref-type="bibr" rid="bib28">Visser et al., 1999</xref>), it still correlates highly with computed tomography and magnetic resonance imaging measurements and represents a good approximation of the real muscle mass (<xref ref-type="bibr" rid="bib2">Buckinx et al., 2018</xref>).</p><p>Other DXA-derived body composition parameters, such as fat mass index (FM/H2) (FMI), appendicular lean mass index (ALM/H2) (ALMI), and trunk/appendicular ratio, were then calculated to complete the analysis and the patient characterization.</p></sec><sec id="s2-3"><title>Circulating bone turnover markers</title><p>Blood chemistry and bone turnover markers: alkaline phosphatase (ALP) and C-terminal telopeptide of type I collagen (CTX) were assessed at baseline, 6 and 12 months. CTX serum levels were measured using the ElectroChemiLuminescenceAssay (ECLIA) kit Elecsys beta-CrossLaps/serum (Roche Diagnostic, Germany) using Cobas e411instruments (Roche); normal ranges were &lt;0.704 ng/ml (men of the age between 50 and 70), &lt;0.854 ng/ml (men &gt;70) with a repeatability (coefficient of variation) CV% of 2.6. Bone ALP serum levels were determined in a two-step procedure. Briefly, total ALP serum activity was measured using the colorimetric method ALP2 (Roche) using Cobas c701 instruments (Roche); normal ranges were 50–116 U/l ± 0.6 with a repeatability CV% of 0.7. Samples were then subjected to electrophoretic separation to separate the different ALP isoforms using the G26 automated system (Sebia, France) equipped with the Interlab specific kit (Italy). Bone ALP activity was calculated as fraction of the total ALP activity related to the percentage of densitometric analysis of the electrophoretic migration.</p></sec><sec id="s2-4"><title>Statistical analysis</title><p>The dataset is available in supplementary material (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). The normal distribution of continuous variables was tested with the Shapiro–Wilk test. Differences between parameters at baseline and 12 months were computed as percentage changes. To test if these changes were significantly different from 0 we used one sample <italic>t</italic>-test, or alternatively the non-parametric sign test.</p><p>Correlations between variables either at baseline and 12 months were expressed as Pearson’s <italic>r</italic> (or alternatively with Spearman <italic>R</italic>, for variables not normally distributed).</p><p>We considered a significant threshold of p &lt; 0.05, and to control for possible false positive results we applied the Bonferroni correction (<inline-formula><mml:math id="inf1"><mml:msup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> , where <italic>k</italic> is the number of hypotheses tested). Given that type I errors cannot decrease (the whole point of Bonferroni adjustments) without inflating type II errors (<xref ref-type="bibr" rid="bib19">Perneger, 1998</xref>), significant results in the raw test but which do not remain so after correction will still be mentioned.</p><p>Our post hoc power analysis, conducted with 29 participants, indicates that our study is powered at 80% to detect a correlation of at least 0.502.</p><p>Statistics were performed using R and SPSS (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.).</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>Twenty-nine patients were included in the BLADE study and their characteristics have been described elsewhere (<xref ref-type="bibr" rid="bib18">Palumbo et al., 2022</xref>). The consort diagram is reported in supplementary material (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). An outlier value of FSH after 12 months was removed from the analysis. Mean FSH serum levels at baseline conditions were 11.9 UI/l (95% confidence intervals [CIs]: 7.6–16.3). Mean FSH serum levels significantly decreased to 1.45 UI/l (95% CIs: 1.01–1.89) after 6 months of degarelix treatment and to 2.4 UI/l (95% CIs: 1.4–3.4) after 12 months. The corresponding percent changes were −77.59% (95% CIs: −86.20 to −68.87) and −59.7% (95% CIs: −80.3 to −39.1, p &lt; 0.001) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Data on changes in body composition parameters, BMD, and bone turnover markers have been published elsewhere (<xref ref-type="bibr" rid="bib17">Palumbo et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Palumbo et al., 2022</xref>; <xref ref-type="bibr" rid="bib4">Dalla Volta et al., 2024</xref>). Correlations between FSH changes and changes in body composition parameters, BMD, and bone turnover markers were not statistically significant, so these data are not presented.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Changes in mean follicle-stimulating hormone (FSH) serum levels from baseline to 6 and 12 months of degarelix treatment.</title><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Data are from BLADE study database.</title></caption><media mimetype="application" mime-subtype="xls" xlink:href="elife-92655-fig1-data1-v1.xls"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92655-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Consort diagram.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92655-fig1-figsupp1-v1.tif"/></fig></fig-group><sec id="s3-1"><title>Relationship between FSH serum levels and body composition, BMD, and bone turnover markers at baseline</title><p>At baseline conditions no relationship was found between FSH serum levels and the following DXA-derived parameters: BMD at left hip and spine, total FBM, total LBM, lean mass at arms and legs, ALMI, ALMI/FBM ratio, and android/gynoid ratio. No correlation was also found between FSH serum levels and serum levels of either ALP or CTX. A direct relationship, although not significant, was found between FSH serum levels and FBM at arms (<italic>r</italic> = 0.36) and legs (<italic>r</italic> = 0.33) (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Baseline relationships between FSH serum levels and BMD, bone turnover markers, and body composition parameters.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3">FSH</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Correlation coefficient</bold></td><td align="left" valign="bottom"><bold>p</bold></td></tr><tr><td align="left" valign="bottom"><bold>TOT BMD</bold></td><td align="char" char="." valign="bottom">0.240</td><td align="char" char="." valign="bottom">0.218</td></tr><tr><td align="left" valign="bottom"><bold>BMD LEFT HIP</bold></td><td align="char" char="." valign="bottom">0.229</td><td align="char" char="." valign="bottom">0.240</td></tr><tr><td align="left" valign="bottom"><bold>BMD L2–L4</bold></td><td align="char" char="." valign="bottom">0.148</td><td align="char" char="." valign="bottom">0.453</td></tr><tr><td align="left" valign="bottom"><bold>CTX</bold></td><td align="char" char="." valign="bottom">−0.115</td><td align="char" char="." valign="bottom">0.560</td></tr><tr><td align="left" valign="bottom"><bold>BONE ALP</bold></td><td align="char" char="." valign="bottom">0.001</td><td align="char" char="." valign="bottom">0.997</td></tr><tr><td align="left" valign="bottom"><bold>TOT fat (g</bold>)</td><td align="char" char="." valign="bottom">0.274</td><td align="char" char="." valign="bottom">0.158</td></tr><tr><td align="left" valign="bottom"><bold>Arm fat (g</bold>)</td><td align="char" char="." valign="bottom">0.363</td><td align="char" char="." valign="bottom">0.058</td></tr><tr><td align="left" valign="bottom"><bold>Leg fat (g</bold>)</td><td align="char" char="." valign="bottom">0.330</td><td align="char" char="." valign="bottom">0.087</td></tr><tr><td align="left" valign="bottom"><bold>Head fat (g</bold>)</td><td align="char" char="." valign="bottom">0.228</td><td align="char" char="." valign="bottom">0.244</td></tr><tr><td align="left" valign="bottom"><bold>Trunk fat (g</bold>)</td><td align="char" char="." valign="bottom">0.249</td><td align="char" char="." valign="bottom">0.202</td></tr><tr><td align="left" valign="bottom"><bold>TOT lean (g</bold>)</td><td align="char" char="." valign="bottom">0.216</td><td align="char" char="." valign="bottom">0.270</td></tr><tr><td align="left" valign="bottom"><bold>Arm lean (g</bold>)</td><td align="char" char="." valign="bottom">0.166</td><td align="char" char="." valign="bottom">0.400</td></tr><tr><td align="left" valign="bottom"><bold>Leg lean (g</bold>)</td><td align="char" char="." valign="bottom">0.197</td><td align="char" char="." valign="bottom">0.315</td></tr><tr><td align="left" valign="bottom"><bold>Head lean (g</bold>)</td><td align="char" char="." valign="bottom">0.250</td><td align="char" char="." valign="bottom">0.199</td></tr><tr><td align="left" valign="bottom"><bold>Trunk lean (g</bold>)</td><td align="char" char="." valign="bottom">0.190</td><td align="char" char="." valign="bottom">0.333</td></tr><tr><td align="left" valign="bottom"><bold>ALMI (appendicular lean/Ht<sup>2</sup></bold>)</td><td align="char" char="." valign="bottom">0.269</td><td align="char" char="." valign="bottom">0.167</td></tr><tr><td align="left" valign="bottom"><bold>ALMI/FBM</bold></td><td align="char" char="." valign="bottom">−0.184</td><td align="char" char="." valign="bottom">0.349</td></tr><tr><td align="left" valign="bottom"><bold>Android/gynoid ratio</bold></td><td align="char" char="." valign="bottom">−0.024</td><td align="char" char="." valign="bottom">0.902</td></tr></tbody></table><table-wrap-foot><fn><p>Data are Spearman R.</p></fn><fn><p>FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP: alkaline phosphatase; ALMI: appendicular lean mass index; Ht<sup>2</sup>: height squared; FBM: fat body mass.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Relationship between FSH serum levels and body composition, BMD, and bone turnover markers after 12 months of degarelix treatment</title><p>The correlation between circulating FSH levels at 6 and 12 months, bone turnover markers evaluated at the same time, BMD and body composition parameters assessed after 12 months is shown in <xref ref-type="table" rid="table2">Table 2</xref>. FSH serum levels assessed after 6 months of degarelix administration showed a direct relationship with total FBM (<italic>r</italic> = 0.49, p = 0.008) and with fat mass evaluated at arms (<italic>r</italic> = 0.53, p = 0.004), trunk (<italic>r</italic> = 0.48, p = 0.009), and legs (<italic>r</italic> = 0.45, p = 0.015). In contrast, FSH serum levels after 6 months of treatment showed an inverse relationship with ALMI/FBM ratio (<italic>r</italic> = −0.58, p = 0.001). FSH measured after 12 months maintained a significant relationship with total FBM (<italic>r</italic> = 0.52, p = 0.006) (<xref ref-type="fig" rid="fig2">Figure 2a</xref>), fat mass at arms (<italic>r</italic> = 0.54, p = 0.004) (<xref ref-type="fig" rid="fig2">Figure 2b</xref>), and fat mass at trunk (<italic>r</italic> = 0.45, p = 0.018) (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). The relationship between FSH and fat mass at legs lost the statistical significance (<italic>r</italic> = 0.33, p = 0.089), while the inverse relationship with ALMI/FBM ratio was confirmed (<italic>r</italic> = −0.64, p = 0.001) (<xref ref-type="fig" rid="fig2">Figure 2d</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Relationship between follicle-stimulating hormone (FSH) serum levels and fat body mass (FBM) (<bold>a</bold>), arm FBM (<bold>b</bold>), trunk FBM (<bold>c</bold>), and appendicular lean mass index (ALMI)/FBM ratio (<bold>d</bold>) after 12 months degarelix treatment.</title><p><italic>R</italic> = Spearman correlation coefficient; p = p-value.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92655-fig2-v1.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Relationships between FSH serum levels and BMD, bone turnover markers, and body composition parameters after 12 months degarelix treatment.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3">FSH at 6 months</th><th align="left" valign="bottom" colspan="2">FSH at 12 months</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>Correlation coefficient</bold></td><td align="left" valign="bottom"><bold>p</bold></td><td align="left" valign="bottom"><bold>Correlation coefficient</bold></td><td align="left" valign="bottom"><bold>p</bold></td></tr><tr><td align="left" valign="bottom"><bold>TOT BMD</bold></td><td align="char" char="." valign="bottom">−0.039</td><td align="char" char="." valign="bottom">0.843</td><td align="char" char="." valign="bottom">−0.107</td><td align="char" char="." valign="bottom">0.595</td></tr><tr><td align="left" valign="bottom"><bold>BMD L2–L4</bold></td><td align="char" char="." valign="bottom">0.102</td><td align="char" char="." valign="bottom">0.604</td><td align="char" char="." valign="bottom">−0.040</td><td align="char" char="." valign="bottom">0.844</td></tr><tr><td align="left" valign="bottom"><bold>BMD LEFT HIP</bold></td><td align="char" char="." valign="bottom">0.030</td><td align="char" char="." valign="bottom">0.881</td><td align="char" char="." valign="bottom">−0.044</td><td align="char" char="." valign="bottom">0.829</td></tr><tr><td align="left" valign="bottom"><bold>CTX</bold></td><td align="char" char="." valign="bottom">0.051</td><td align="char" char="." valign="bottom">0.796</td><td align="char" char="." valign="bottom">0.055</td><td align="char" char="." valign="bottom">0.785</td></tr><tr><td align="left" valign="bottom"><bold>BONE ALP</bold></td><td align="char" char="." valign="bottom">0.174</td><td align="char" char="." valign="bottom">0.376</td><td align="char" char="." valign="bottom">0.227</td><td align="char" char="." valign="bottom">0.256</td></tr><tr><td align="left" valign="bottom"><bold>TOT fat (g</bold>)</td><td align="char" char="." valign="bottom"><bold>0.490</bold></td><td align="char" char="." valign="bottom"><bold>0.008</bold></td><td align="char" char="." valign="bottom"><bold>0.518</bold></td><td align="char" char="." valign="bottom"><bold>0.006</bold></td></tr><tr><td align="left" valign="bottom"><bold>Arm fat (g</bold>)</td><td align="char" char="." valign="bottom"><bold>0.532</bold></td><td align="char" char="." valign="bottom"><bold>0.004</bold></td><td align="char" char="." valign="bottom"><bold>0.541</bold></td><td align="char" char="." valign="bottom"><bold>0.004</bold></td></tr><tr><td align="left" valign="bottom"><bold>Leg fat (g</bold>)</td><td align="char" char="." valign="bottom"><bold>0.454</bold></td><td align="char" char="." valign="bottom"><bold>0.015</bold></td><td align="char" char="." valign="bottom">0.328</td><td align="char" char="." valign="bottom">0.089</td></tr><tr><td align="left" valign="bottom"><bold>Head fat (g</bold>)</td><td align="char" char="." valign="bottom">0.187</td><td align="char" char="." valign="bottom">0.341</td><td align="char" char="." valign="bottom">0.093</td><td align="char" char="." valign="bottom">0.644</td></tr><tr><td align="left" valign="bottom"><bold>Trunk fat (g</bold>)</td><td align="char" char="." valign="bottom"><bold>0.483</bold></td><td align="char" char="." valign="bottom"><bold>0.009</bold></td><td align="char" char="." valign="bottom"><bold>0.452</bold></td><td align="char" char="." valign="bottom"><bold>0.018</bold></td></tr><tr><td align="left" valign="bottom"><bold>TOT lean (g</bold>)</td><td align="char" char="." valign="bottom">0.029</td><td align="char" char="." valign="bottom">0.885</td><td align="char" char="." valign="bottom">−0.036</td><td align="char" char="." valign="bottom">0.859</td></tr><tr><td align="left" valign="bottom"><bold>Arm lean (g</bold>)</td><td align="char" char="." valign="bottom">0.041</td><td align="char" char="." valign="bottom">0.837</td><td align="char" char="." valign="bottom">0.028</td><td align="char" char="." valign="bottom">0.889</td></tr><tr><td align="left" valign="bottom"><bold>Leg lean (g</bold>)</td><td align="char" char="." valign="bottom">−0.176</td><td align="char" char="." valign="bottom">0.371</td><td align="char" char="." valign="bottom">−0.285</td><td align="char" char="." valign="bottom">0.149</td></tr><tr><td align="left" valign="bottom"><bold>Head lean (g</bold>)</td><td align="char" char="." valign="bottom">0.086</td><td align="char" char="." valign="bottom">0.663</td><td align="char" char="." valign="bottom">−0.006</td><td align="char" char="." valign="bottom">0.977</td></tr><tr><td align="left" valign="bottom"><bold>Trunk lean (g</bold>)</td><td align="char" char="." valign="bottom">0.161</td><td align="char" char="." valign="bottom">0.414</td><td align="char" char="." valign="bottom">0.021</td><td align="char" char="." valign="bottom">0.916</td></tr><tr><td align="left" valign="bottom"><bold>ALMI (appendicular lean/Ht<sup>2</sup></bold>)</td><td align="char" char="." valign="bottom">−0.229</td><td align="char" char="." valign="bottom">0.241</td><td align="char" char="." valign="bottom">−0.265</td><td align="char" char="." valign="bottom">0.181</td></tr><tr><td align="left" valign="bottom"><bold>ALMI/FBM</bold></td><td align="char" char="." valign="bottom"><bold>−0.581</bold></td><td align="char" char="." valign="bottom">0.001<xref ref-type="table-fn" rid="table2fn3"><sup>*</sup></xref></td><td align="char" char="." valign="bottom"><bold>−0.604</bold></td><td align="char" char="." valign="bottom">0.001<xref ref-type="table-fn" rid="table2fn3"><sup>*</sup></xref></td></tr><tr><td align="left" valign="bottom"><bold>Android/gynoid ratio</bold></td><td align="char" char="." valign="bottom">0.142</td><td align="char" char="." valign="bottom">0.472</td><td align="char" char="." valign="bottom">0.231</td><td align="char" char="." valign="bottom">0.246</td></tr></tbody></table><table-wrap-foot><fn><p>Data are Spearman <italic>R</italic>.</p></fn><fn><p>Bold values are those attaining statistical significance.</p></fn><fn id="table2fn3"><label>*</label><p>Still significant after Bonferroni correction.</p></fn><fn><p>FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP: alkaline phosphatase; ALMI: appendicular lean mass index; Ht<sup>2</sup>: height squared; FBM: fat body mass.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>ADT in PC patients leads to an increase in fat mass and to a decrease in lean mass, thus increasing the risk of sarcopenic obesity. In addition, ADT has also a negative impact on skeletal fragility, which increases the risk of fractures. During the recent years, there has been consistent evidence that alterations in body composition could contribute to determine skeletal fragility in patients under ADT, such as well demonstrated in other forms of male hypogonadism (<xref ref-type="bibr" rid="bib27">Vena et al., 2023</xref>). However, the determinants of altered body composition in male hypogonadism and in ADTs have not been completely defined. As a matter of fact, low testosterone values do not seem to be the only determinant of sarcopenic obesity in males with hypogonadism. In this context, FSH values might play a role. In fact, among its extragonadal effects, FSH directly affects adipogenesis, lean mass and bone turnover (<xref ref-type="bibr" rid="bib10">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Rojekar et al., 2023</xref>; <xref ref-type="bibr" rid="bib29">Zaidi et al., 2023</xref>; <xref ref-type="bibr" rid="bib6">Gera et al., 2022</xref>).</p><p>As demonstrated in other studies prospectively evaluating circulating FSH levels after treatment with LHRH agonists and antagonists (<xref ref-type="bibr" rid="bib9">Klotz et al., 2008</xref>), degarelix administration consistently reduced FSH values, although values might be variable among individuals under ADT. In this context, it is reasonable to hypothesize that variable values of FSH might directly influence body composition and skeletal fragility.</p><p>This ancillary analysis of the BLADE study shows that higher serum levels of FSH during degarelix treatment were significantly associated with higher total, limbs, and trunk fat mass. Moreover, higher FSH values under ADT were associated with lower ALMI/FBM ratio, a parameter that identifies patients at high risk for sarcopenic obesity. We can infer therefore that the effect was caused by the direct relationship of FBM since there was no correlation between lean mass and FSH in this study. These associations were not significant before starting degarelix, suggesting that sex hormones might counteract FSH effect on body composition at baseline conditions, whereas this effect becomes more evident after ADT. According to these data, small changes in FSH can result in significant changes in body composition in a condition of androgen and estrogen deprivation. However, since sex hormones were not measured in our patients, it was unclear whether the possible variability in testosterone values during degarelix treatment (<xref ref-type="bibr" rid="bib8">Kamada et al., 2024</xref>) might have influenced the detrimental effects of FSH and body composition. Indeed, the protocol of BLADE study did not include measurement of testosterone values, since radioimmunoassay and chemiluminescence assay used in clinical practice could overestimate testosterone levels in majority of patients under ADTs, leaving a concern of misdiagnosing truly castrate patients as being inadequately treated (<xref ref-type="bibr" rid="bib26">Tiwari et al., 2022</xref>).</p><p>It is known that one of the most noticeable differences of LHRH antagonists compared to LHRH agonists are FSH levels during therapy, which are mildly higher with LHRH agonists compared to LHRH antagonists. According to our data, PC patients treated with LHRH antagonists may experience less body composition changes due to lower FSH residual values (<xref ref-type="bibr" rid="bib9">Klotz et al., 2008</xref>; <xref ref-type="bibr" rid="bib12">Margel et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Abufaraj et al., 2021</xref>).</p><p>Unlike other settings, FSH values before and after degarelix did not correlate with either BMD or bone turnover markers.</p><p>To our knowledge, this is the first study showing an association between circulating FSH levels and body composition in PC patients undergoing ADT. However, this study suffers from all the limitations of ancillary studies. Therefore, the results obtained are to be considered as hypothesis generating and cannot be generalized.</p><p>In conclusion, the findings of this study suggest that FSH serum levels after ADT could impact body composition – FBM in particular – in PC patients undergoing ADT.</p><p>Of course further investigation is required to establish the association between FSH serum levels, measured during ADT, and sarcopenic obesity risk in PC patients. However, this is an area of great interest.</p><p>FSH could be a promising marker in monitoring PC patients during ADT in order to identify those who are more vulnerable and at greater risk of alterations in body composition, which can be captured and measured reliably by DXA (<xref ref-type="bibr" rid="bib14">Mazziotti et al., 2024</xref>).</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>L Rinaudo is affiliated with Tecnologie Avanzate S.r.l. The author has no financial interests to declare</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Investigation</p></fn><fn fn-type="con" id="con13"><p>Investigation</p></fn><fn fn-type="con" id="con14"><p>Investigation</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Investigation</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Writing – original draft</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Clinical trial registration clinicalTrials.gov NCT03202381, EudraCT Number 2016-004210-10.</p></fn><fn fn-type="other"><p>The study was carried out in accordance with the Declaration of Helsinki Principles and Good Clinical Practices and was approved by the Ethics Committee of Brescia (approval number NP2540).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Clinical and demographical data of enrolled patients at baseline.</title></caption><media xlink:href="elife-92655-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92655-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="repstand1"><label>Reporting standard 1.</label><caption><title>STROBE statement for prospective study.</title></caption><media xlink:href="elife-92655-repstand1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript. Source data have been provided in an excel file labelled Source data 1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors are grateful to the following associations: AOB (Associazione Oncologica Bresciana) and FIRM-Onlus (Fondazione Internazionale di Ricerca in Medicina Onlus) for the continuous support. This research was partially funded by Ferring Pharmaceuticals. The funder had no role in design and conduct of the study, collection, management, analysis, and interpretation of the data and in preparation, review, or approval of the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abufaraj</surname><given-names>M</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Haddad</surname><given-names>A</given-names></name><name><surname>Al-Ani</surname><given-names>H</given-names></name><name><surname>Abusubaih</surname><given-names>L</given-names></name><name><surname>Moschini</surname><given-names>M</given-names></name><name><surname>Briganti</surname><given-names>A</given-names></name><name><surname>Karakiewicz</surname><given-names>PI</given-names></name><name><surname>Shariat</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: A meta-analysis of randomized controlled trials</article-title><source>European Urology</source><volume>79</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2020.06.002</pub-id><pub-id pub-id-type="pmid">32605859</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckinx</surname><given-names>F</given-names></name><name><surname>Landi</surname><given-names>F</given-names></name><name><surname>Cesari</surname><given-names>M</given-names></name><name><surname>Fielding</surname><given-names>RA</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Engelke</surname><given-names>K</given-names></name><name><surname>Maggi</surname><given-names>S</given-names></name><name><surname>Dennison</surname><given-names>E</given-names></name><name><surname>Al-Daghri</surname><given-names>NM</given-names></name><name><surname>Allepaerts</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Bautmans</surname><given-names>I</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name><name><surname>Bruyère</surname><given-names>O</given-names></name><name><surname>Cederholm</surname><given-names>T</given-names></name><name><surname>Cerreta</surname><given-names>F</given-names></name><name><surname>Cherubini</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Cruz-Jentoft</surname><given-names>A</given-names></name><name><surname>McCloskey</surname><given-names>E</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name><name><surname>Kaufman</surname><given-names>JM</given-names></name><name><surname>Laslop</surname><given-names>A</given-names></name><name><surname>Petermans</surname><given-names>J</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name><name><surname>Rizzoli</surname><given-names>R</given-names></name><name><surname>Robinson</surname><given-names>S</given-names></name><name><surname>Rolland</surname><given-names>Y</given-names></name><name><surname>Rueda</surname><given-names>R</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pitfalls in the measurement of muscle mass: a need for a reference standard</article-title><source>Journal of Cachexia, Sarcopenia and Muscle</source><volume>9</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1002/jcsm.12268</pub-id><pub-id pub-id-type="pmid">29349935</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornford</surname><given-names>P</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Bolla</surname><given-names>M</given-names></name><name><surname>Briers</surname><given-names>E</given-names></name><name><surname>De Santis</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>T</given-names></name><name><surname>Henry</surname><given-names>AM</given-names></name><name><surname>Joniau</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>TB</given-names></name><name><surname>Mason</surname><given-names>MD</given-names></name><name><surname>van der Poel</surname><given-names>HG</given-names></name><name><surname>van der Kwast</surname><given-names>TH</given-names></name><name><surname>Rouvière</surname><given-names>O</given-names></name><name><surname>Wiegel</surname><given-names>T</given-names></name><name><surname>Mottet</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Eau-estro-siog guidelines on prostate cancer: part ii: treatment of relapsing, metastatic, and castration-resistant prostate cancer</article-title><source>European Urology</source><volume>71</volume><fpage>630</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2016.08.002</pub-id><pub-id pub-id-type="pmid">27591931</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalla Volta</surname><given-names>A</given-names></name><name><surname>Palumbo</surname><given-names>C</given-names></name><name><surname>Zamboni</surname><given-names>S</given-names></name><name><surname>Mazziotti</surname><given-names>G</given-names></name><name><surname>Triggiani</surname><given-names>L</given-names></name><name><surname>Zamparini</surname><given-names>M</given-names></name><name><surname>Maffezzoni</surname><given-names>F</given-names></name><name><surname>Rinaudo</surname><given-names>L</given-names></name><name><surname>Bergamini</surname><given-names>M</given-names></name><name><surname>Di Meo</surname><given-names>N</given-names></name><name><surname>Caramella</surname><given-names>I</given-names></name><name><surname>Valcamonico</surname><given-names>F</given-names></name><name><surname>Borghetti</surname><given-names>P</given-names></name><name><surname>Guerini</surname><given-names>A</given-names></name><name><surname>Farina</surname><given-names>D</given-names></name><name><surname>Antonelli</surname><given-names>A</given-names></name><name><surname>Simeone</surname><given-names>C</given-names></name><name><surname>Berruti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study</article-title><source>Journal of Endocrinological Investigation</source><volume>47</volume><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1007/s40618-023-02150-z</pub-id><pub-id pub-id-type="pmid">37458931</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Khoudary</surname><given-names>SR</given-names></name><name><surname>Santoro</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Tepper</surname><given-names>PG</given-names></name><name><surname>Brooks</surname><given-names>MM</given-names></name><name><surname>Thurston</surname><given-names>RC</given-names></name><name><surname>Janssen</surname><given-names>I</given-names></name><name><surname>Harlow</surname><given-names>SD</given-names></name><name><surname>Barinas-Mitchell</surname><given-names>E</given-names></name><name><surname>Selzer</surname><given-names>F</given-names></name><name><surname>Derby</surname><given-names>CA</given-names></name><name><surname>Jackson</surname><given-names>EA</given-names></name><name><surname>McConnell</surname><given-names>D</given-names></name><name><surname>Matthews</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause</article-title><source>European Journal of Preventive Cardiology</source><volume>23</volume><fpage>694</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1177/2047487315607044</pub-id><pub-id pub-id-type="pmid">26385249</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gera</surname><given-names>S</given-names></name><name><surname>Kuo</surname><given-names>TC</given-names></name><name><surname>Gumerova</surname><given-names>AA</given-names></name><name><surname>Korkmaz</surname><given-names>F</given-names></name><name><surname>Sant</surname><given-names>D</given-names></name><name><surname>DeMambro</surname><given-names>V</given-names></name><name><surname>Sudha</surname><given-names>K</given-names></name><name><surname>Padilla</surname><given-names>A</given-names></name><name><surname>Prevot</surname><given-names>G</given-names></name><name><surname>Munitz</surname><given-names>J</given-names></name><name><surname>Teunissen</surname><given-names>A</given-names></name><name><surname>van Leent</surname><given-names>MMT</given-names></name><name><surname>Post</surname><given-names>T</given-names></name><name><surname>Fernandes</surname><given-names>JC</given-names></name><name><surname>Netto</surname><given-names>J</given-names></name><name><surname>Sultana</surname><given-names>F</given-names></name><name><surname>Shelly</surname><given-names>E</given-names></name><name><surname>Rojekar</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Cullen</surname><given-names>L</given-names></name><name><surname>Chatterjee</surname><given-names>J</given-names></name><name><surname>Pallapati</surname><given-names>A</given-names></name><name><surname>Miyashita</surname><given-names>S</given-names></name><name><surname>Kannangara</surname><given-names>H</given-names></name><name><surname>Bhongade</surname><given-names>M</given-names></name><name><surname>Sengupta</surname><given-names>P</given-names></name><name><surname>Ievleva</surname><given-names>K</given-names></name><name><surname>Muradova</surname><given-names>V</given-names></name><name><surname>Batista</surname><given-names>R</given-names></name><name><surname>Robinson</surname><given-names>C</given-names></name><name><surname>Macdonald</surname><given-names>A</given-names></name><name><surname>Hutchison</surname><given-names>S</given-names></name><name><surname>Saxena</surname><given-names>M</given-names></name><name><surname>Meseck</surname><given-names>M</given-names></name><name><surname>Caminis</surname><given-names>J</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>New</surname><given-names>MI</given-names></name><name><surname>Ryu</surname><given-names>V</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Cao</surname><given-names>JJ</given-names></name><name><surname>Zaidi</surname><given-names>N</given-names></name><name><surname>Fayad</surname><given-names>ZA</given-names></name><name><surname>Lizneva</surname><given-names>D</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>FSH-blocking therapeutic for osteoporosis</article-title><source>eLife</source><volume>11</volume><elocation-id>e78022</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.78022</pub-id><pub-id pub-id-type="pmid">36125123</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guligowska</surname><given-names>A</given-names></name><name><surname>Chrzastek</surname><given-names>Z</given-names></name><name><surname>Pawlikowski</surname><given-names>M</given-names></name><name><surname>Pigłowska</surname><given-names>M</given-names></name><name><surname>Pisarek</surname><given-names>H</given-names></name><name><surname>Winczyk</surname><given-names>K</given-names></name><name><surname>Kostka</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gonadotropins at advanced age - perhaps they are not so bad? Correlations between gonadotropins and sarcopenia indicators in older adults</article-title><source>Frontiers in Endocrinology</source><volume>12</volume><elocation-id>797243</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2021.797243</pub-id><pub-id pub-id-type="pmid">35002975</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamada</surname><given-names>S</given-names></name><name><surname>Sakamoto</surname><given-names>S</given-names></name><name><surname>Kinoshita</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Kamasako</surname><given-names>T</given-names></name><name><surname>Yamase</surname><given-names>R</given-names></name><name><surname>Junryo</surname><given-names>R</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Sangjon</surname><given-names>P</given-names></name><name><surname>Takei</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Iguchi</surname><given-names>T</given-names></name><name><surname>Mizokami</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Akakura</surname><given-names>K</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix</article-title><source>The Prostate</source><volume>01</volume><elocation-id>4679</elocation-id><pub-id pub-id-type="doi">10.1002/pros.24679</pub-id><pub-id pub-id-type="pmid">38413843</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klotz</surname><given-names>L</given-names></name><name><surname>Boccon-Gibod</surname><given-names>L</given-names></name><name><surname>Shore</surname><given-names>ND</given-names></name><name><surname>Andreou</surname><given-names>C</given-names></name><name><surname>Persson</surname><given-names>BE</given-names></name><name><surname>Cantor</surname><given-names>P</given-names></name><name><surname>Jensen</surname><given-names>JK</given-names></name><name><surname>Olesen</surname><given-names>TK</given-names></name><name><surname>Schröder</surname><given-names>FH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer</article-title><source>BJU International</source><volume>102</volume><fpage>1531</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.08183.x</pub-id><pub-id pub-id-type="pmid">19035858</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name><name><surname>Rendina-Ruedy</surname><given-names>E</given-names></name><name><surname>DeMambro</surname><given-names>VE</given-names></name><name><surname>Dhawan</surname><given-names>S</given-names></name><name><surname>Abu-Amer</surname><given-names>W</given-names></name><name><surname>Izadmehr</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Shin</surname><given-names>AC</given-names></name><name><surname>Latif</surname><given-names>R</given-names></name><name><surname>Thangeswaran</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shnayder</surname><given-names>V</given-names></name><name><surname>Robinson</surname><given-names>ST</given-names></name><name><surname>Yu</surname><given-names>YE</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>LL</given-names></name><name><surname>Oberlin</surname><given-names>DJ</given-names></name><name><surname>Davies</surname><given-names>TF</given-names></name><name><surname>Reagan</surname><given-names>MR</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>TR</given-names></name><name><surname>Epstein</surname><given-names>S</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Avadhani</surname><given-names>NG</given-names></name><name><surname>New</surname><given-names>MI</given-names></name><name><surname>Molina</surname><given-names>H</given-names></name><name><surname>van Klinken</surname><given-names>JB</given-names></name><name><surname>Guo</surname><given-names>EX</given-names></name><name><surname>Buettner</surname><given-names>C</given-names></name><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Bian</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Blocking FSH induces thermogenic adipose tissue and reduces body fat</article-title><source>Nature</source><volume>546</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/nature22342</pub-id><pub-id pub-id-type="pmid">28538730</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lizneva</surname><given-names>D</given-names></name><name><surname>Rahimova</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Atabiekov</surname><given-names>I</given-names></name><name><surname>Javaid</surname><given-names>S</given-names></name><name><surname>Alamoush</surname><given-names>B</given-names></name><name><surname>Taneja</surname><given-names>C</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fsh beyond fertility</article-title><source>Frontiers in Endocrinology</source><volume>10</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2019.00136</pub-id><pub-id pub-id-type="pmid">30941099</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margel</surname><given-names>D</given-names></name><name><surname>Peer</surname><given-names>A</given-names></name><name><surname>Ber</surname><given-names>Y</given-names></name><name><surname>Shavit-Grievink</surname><given-names>L</given-names></name><name><surname>Tabachnik</surname><given-names>T</given-names></name><name><surname>Sela</surname><given-names>S</given-names></name><name><surname>Witberg</surname><given-names>G</given-names></name><name><surname>Baniel</surname><given-names>J</given-names></name><name><surname>Kedar</surname><given-names>D</given-names></name><name><surname>Duivenvoorden</surname><given-names>WCM</given-names></name><name><surname>Rosenbaum</surname><given-names>E</given-names></name><name><surname>Pinthus</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cardiovascular morbidity in a randomized trial comparing gnrh agonist and gnrh antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease</article-title><source>The Journal of Urology</source><volume>202</volume><fpage>1199</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1097/JU.0000000000000384</pub-id><pub-id pub-id-type="pmid">31188734</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattick</surname><given-names>LJ</given-names></name><name><surname>Bea</surname><given-names>JW</given-names></name><name><surname>Singh</surname><given-names>L</given-names></name><name><surname>Hovey</surname><given-names>KM</given-names></name><name><surname>Banack</surname><given-names>HR</given-names></name><name><surname>Wactawski-Wende</surname><given-names>J</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Funk</surname><given-names>JL</given-names></name><name><surname>Ochs-Balcom</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Serum follicle-stimulating hormone and 5-year change in adiposity in healthy postmenopausal women</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>107</volume><fpage>e3455</fpage><lpage>e3462</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgac238</pub-id><pub-id pub-id-type="pmid">35435955</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazziotti</surname><given-names>G</given-names></name><name><surname>Lania</surname><given-names>AG</given-names></name><name><surname>Laganà</surname><given-names>M</given-names></name><name><surname>Berruti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Prediction of fragility fractures in men with prostate cancer under androgen deprivation therapy: the importance of a multidisciplinary approach using a mini-invasive diagnostic tool</article-title><source>Endocrine</source><volume>83</volume><fpage>594</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1007/s12020-023-03613-2</pub-id><pub-id pub-id-type="pmid">38112923</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottet</surname><given-names>N</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Bolla</surname><given-names>M</given-names></name><name><surname>Briers</surname><given-names>E</given-names></name><name><surname>Cumberbatch</surname><given-names>MG</given-names></name><name><surname>De Santis</surname><given-names>M</given-names></name><name><surname>Fossati</surname><given-names>N</given-names></name><name><surname>Gross</surname><given-names>T</given-names></name><name><surname>Henry</surname><given-names>AM</given-names></name><name><surname>Joniau</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>TB</given-names></name><name><surname>Mason</surname><given-names>MD</given-names></name><name><surname>Matveev</surname><given-names>VB</given-names></name><name><surname>Moldovan</surname><given-names>PC</given-names></name><name><surname>van den Bergh</surname><given-names>RCN</given-names></name><name><surname>Van den Broeck</surname><given-names>T</given-names></name><name><surname>van der Poel</surname><given-names>HG</given-names></name><name><surname>van der Kwast</surname><given-names>TH</given-names></name><name><surname>Rouvière</surname><given-names>O</given-names></name><name><surname>Schoots</surname><given-names>IG</given-names></name><name><surname>Wiegel</surname><given-names>T</given-names></name><name><surname>Cornford</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Eau-estro-siog guidelines on prostate cancer part 1: screening, diagnosis, and local treatment with curative intent</article-title><source>European Urology</source><volume>71</volume><fpage>618</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2016.08.003</pub-id><pub-id pub-id-type="pmid">27568654</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munir</surname><given-names>JA</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Bauer</surname><given-names>K</given-names></name><name><surname>Bindeman</surname><given-names>J</given-names></name><name><surname>Byrd</surname><given-names>C</given-names></name><name><surname>Feuerstein</surname><given-names>IM</given-names></name><name><surname>Villines</surname><given-names>TC</given-names></name><name><surname>Taylor</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The perimenopausal atherosclerosis transition: relationships between calcified and noncalcified coronary, aortic, and carotid atherosclerosis and risk factors and hormone levels</article-title><source>Menopause</source><volume>19</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1097/gme.0b013e318221bc8d</pub-id><pub-id pub-id-type="pmid">21900851</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>C</given-names></name><name><surname>Antonelli</surname><given-names>A</given-names></name><name><surname>Triggiani</surname><given-names>L</given-names></name><name><surname>Dalla Volta</surname><given-names>A</given-names></name><name><surname>Maffezzoni</surname><given-names>F</given-names></name><name><surname>Zamboni</surname><given-names>S</given-names></name><name><surname>Borghetti</surname><given-names>P</given-names></name><name><surname>Rinaudo</surname><given-names>L</given-names></name><name><surname>Valcamonico</surname><given-names>F</given-names></name><name><surname>Maroldi</surname><given-names>R</given-names></name><name><surname>Magrini</surname><given-names>SM</given-names></name><name><surname>Simeone</surname><given-names>C</given-names></name><name><surname>Berruti</surname><given-names>A</given-names></name><name><surname>Francavilla</surname><given-names>S</given-names></name><name><surname>Furlan</surname><given-names>M</given-names></name><name><surname>Gheza</surname><given-names>A</given-names></name><name><surname>Veccia</surname><given-names>A</given-names></name><name><surname>Guerini</surname><given-names>A</given-names></name><collab>Collaborators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Changes in body composition and lipid profile in prostate cancer patients without bone metastases given degarelix treatment: the blade prospective cohort study</article-title><source>Prostate Cancer and Prostatic Diseases</source><volume>24</volume><fpage>852</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1038/s41391-021-00345-0</pub-id><pub-id pub-id-type="pmid">33723362</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>C</given-names></name><name><surname>Dalla Volta</surname><given-names>A</given-names></name><name><surname>Zamboni</surname><given-names>S</given-names></name><name><surname>Mazziotti</surname><given-names>G</given-names></name><name><surname>Zamparini</surname><given-names>M</given-names></name><name><surname>Triggiani</surname><given-names>L</given-names></name><name><surname>Borghetti</surname><given-names>P</given-names></name><name><surname>Maffezzoni</surname><given-names>F</given-names></name><name><surname>Bresciani</surname><given-names>R</given-names></name><name><surname>Rinaudo</surname><given-names>L</given-names></name><name><surname>Valcamonico</surname><given-names>F</given-names></name><name><surname>Farina</surname><given-names>D</given-names></name><name><surname>Magrini</surname><given-names>SM</given-names></name><name><surname>Antonelli</surname><given-names>A</given-names></name><name><surname>Simeone</surname><given-names>C</given-names></name><name><surname>Berruti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Effect of degarelix administration on bone health in prostate cancer patients without bone metastases: the blade study</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>107</volume><fpage>3398</fpage><lpage>3407</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgac489</pub-id><pub-id pub-id-type="pmid">35971857</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perneger</surname><given-names>TV</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>What’s wrong with bonferroni adjustments</article-title><source>BMJ</source><volume>316</volume><fpage>1236</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1136/bmj.316.7139.1236</pub-id><pub-id pub-id-type="pmid">9553006</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojekar</surname><given-names>S</given-names></name><name><surname>Pallapati</surname><given-names>AR</given-names></name><name><surname>Gimenez-Roig</surname><given-names>J</given-names></name><name><surname>Korkmaz</surname><given-names>F</given-names></name><name><surname>Sultana</surname><given-names>F</given-names></name><name><surname>Sant</surname><given-names>D</given-names></name><name><surname>Haeck</surname><given-names>CM</given-names></name><name><surname>Macdonald</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Barak</surname><given-names>O</given-names></name><name><surname>Meseck</surname><given-names>M</given-names></name><name><surname>Caminis</surname><given-names>J</given-names></name><name><surname>Lizneva</surname><given-names>D</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentration</article-title><source>eLife</source><volume>12</volume><elocation-id>e88898</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.88898</pub-id><pub-id pub-id-type="pmid">37334968</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senapati</surname><given-names>S</given-names></name><name><surname>Gracia</surname><given-names>CR</given-names></name><name><surname>Freeman</surname><given-names>EW</given-names></name><name><surname>Sammel</surname><given-names>MD</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Schwab</surname><given-names>RJ</given-names></name><name><surname>Pien</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hormone variations associated with quantitative fat measures in the menopausal transition</article-title><source>Climacteric</source><volume>17</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.3109/13697137.2013.845876</pub-id><pub-id pub-id-type="pmid">24066661</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>D</given-names></name><name><surname>Cerqueira</surname><given-names>JCM</given-names></name><name><surname>Oliveira Cipriano Torres</surname><given-names>D</given-names></name><name><surname>Santos</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Endogenous sex hormones are not associated with subclinical atherosclerosis in menopausal women</article-title><source>Minerva Ginecologica</source><volume>01</volume><fpage>297</fpage><lpage>302</lpage></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowers</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Tomey</surname><given-names>K</given-names></name><name><surname>Karvonen-Gutierrez</surname><given-names>C</given-names></name><name><surname>Jannausch</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yosef</surname><given-names>M</given-names></name><name><surname>Symons</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Changes in body composition in women over six years at midlife: ovarian and chronological aging</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>92</volume><fpage>895</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-1393</pub-id><pub-id pub-id-type="pmid">17192296</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Sharrow</surname><given-names>AC</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Papachristou</surname><given-names>DJ</given-names></name><name><surname>Zaidi</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>LL</given-names></name><name><surname>Yaroslavskiy</surname><given-names>BB</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zallone</surname><given-names>A</given-names></name><name><surname>Sairam</surname><given-names>MR</given-names></name><name><surname>Kumar</surname><given-names>TR</given-names></name><name><surname>Bo</surname><given-names>W</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Cardoso-Landa</surname><given-names>L</given-names></name><name><surname>Schaffler</surname><given-names>MB</given-names></name><name><surname>Moonga</surname><given-names>BS</given-names></name><name><surname>Blair</surname><given-names>HC</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>FSH directly regulates bone mass</article-title><source>Cell</source><volume>125</volume><fpage>247</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.01.051</pub-id><pub-id pub-id-type="pmid">16630814</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thurston</surname><given-names>RC</given-names></name><name><surname>Sowers</surname><given-names>MR</given-names></name><name><surname>Sternfeld</surname><given-names>B</given-names></name><name><surname>Gold</surname><given-names>EB</given-names></name><name><surname>Bromberger</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Joffe</surname><given-names>H</given-names></name><name><surname>Crandall</surname><given-names>CJ</given-names></name><name><surname>Waetjen</surname><given-names>LE</given-names></name><name><surname>Matthews</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Gains in body fat and vasomotor symptom reporting over the menopausal transition: the study of women’s health across the nation</article-title><source>American Journal of Epidemiology</source><volume>170</volume><fpage>766</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1093/aje/kwp203</pub-id><pub-id pub-id-type="pmid">19675142</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>R</given-names></name><name><surname>Lajkosz</surname><given-names>K</given-names></name><name><surname>Berjaoui</surname><given-names>M</given-names></name><name><surname>Qaoud</surname><given-names>Y</given-names></name><name><surname>Kenk</surname><given-names>M</given-names></name><name><surname>Woffendin</surname><given-names>C</given-names></name><name><surname>Caron</surname><given-names>P</given-names></name><name><surname>Guillemette</surname><given-names>C</given-names></name><name><surname>Fleshner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT)</article-title><source>Urologic Oncology</source><volume>40</volume><elocation-id>193</elocation-id><pub-id pub-id-type="doi">10.1016/j.urolonc.2022.03.011</pub-id><pub-id pub-id-type="pmid">35437219</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vena</surname><given-names>W</given-names></name><name><surname>Carrone</surname><given-names>F</given-names></name><name><surname>Delbarba</surname><given-names>A</given-names></name><name><surname>Akpojiyovbi</surname><given-names>O</given-names></name><name><surname>Pezzaioli</surname><given-names>LC</given-names></name><name><surname>Facondo</surname><given-names>P</given-names></name><name><surname>Cappelli</surname><given-names>C</given-names></name><name><surname>Leonardi</surname><given-names>L</given-names></name><name><surname>Balzarini</surname><given-names>L</given-names></name><name><surname>Farina</surname><given-names>D</given-names></name><name><surname>Pizzocaro</surname><given-names>A</given-names></name><name><surname>Lania</surname><given-names>AG</given-names></name><name><surname>Mazziotti</surname><given-names>G</given-names></name><name><surname>Ferlin</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Body composition, trabecular bone score and vertebral fractures in subjects with klinefelter syndrome</article-title><source>Journal of Endocrinological Investigation</source><volume>46</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1007/s40618-022-01901-8</pub-id><pub-id pub-id-type="pmid">36030302</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Fuerst</surname><given-names>T</given-names></name><name><surname>Lang</surname><given-names>T</given-names></name><name><surname>Salamone</surname><given-names>L</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Validity of fan-beam dual-energy x-ray absorptiometry for measuring fat-free mass and leg muscle mass: health, aging, and body composition study--dual-energy x-ray absorptiometry and body composition working group</article-title><source>Journal of Applied Physiology</source><volume>87</volume><fpage>1513</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1152/jappl.1999.87.4.1513</pub-id><pub-id pub-id-type="pmid">10517786</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaidi</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Mathew</surname><given-names>M</given-names></name><name><surname>Korkmaz</surname><given-names>F</given-names></name><name><surname>Sultana</surname><given-names>F</given-names></name><name><surname>Miyashita</surname><given-names>S</given-names></name><name><surname>Gumerova</surname><given-names>AA</given-names></name><name><surname>Frolinger</surname><given-names>T</given-names></name><name><surname>Moldavski</surname><given-names>O</given-names></name><name><surname>Barak</surname><given-names>O</given-names></name><name><surname>Pallapati</surname><given-names>A</given-names></name><name><surname>Rojekar</surname><given-names>S</given-names></name><name><surname>Caminis</surname><given-names>J</given-names></name><name><surname>Ginzburg</surname><given-names>Y</given-names></name><name><surname>Ryu</surname><given-names>V</given-names></name><name><surname>Davies</surname><given-names>TF</given-names></name><name><surname>Lizneva</surname><given-names>D</given-names></name><name><surname>Rosen</surname><given-names>CJ</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Bone circuitry and interorgan skeletal crosstalk</article-title><source>eLife</source><volume>12</volume><elocation-id>e83142</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.83142</pub-id><pub-id pub-id-type="pmid">36656634</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92655.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Se-Min</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.10.24.23297490" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.10.24.23297490"/></front-stub><body><p>This ancillary study from the BLADE study provided valuable findings regarding FSH as a predictor of sarcopenic obesity in patients using the LHRH antagonist Degarelix, suggesting a potential direct effect of FSH on fat. The study design and analysis were solid, and the limitations of the study such as the small sample size and lack of sex hormone analysis-were properly addressed.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92655.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kim</surname><given-names>Se-Min</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Gennari</surname><given-names>Luigi</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tevnk56</institution-id><institution>University of Siena</institution></institution-wrap><country>Italy</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.10.24.23297490">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2023.10.24.23297490v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Diane Harper as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions (for the authors):</p><p>1. The relationship between FSH and body composition can be further elucidated by incorporating changes in testosterone levels and addressing other major confounding variables in the analysis.</p><p>2. The claim of sarcopenia and FSH, postulated by using ALBI/FBM as a variable, seems weak and requires additional supportive evidence.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>If the authors can provide, the additional regression model might be helpful to understand the direct relationship between FSH and fat, especially sex hormones.</p><p>Please address the discrepancy of correlation coefficient (r) between FSH and ALBI in this manuscript and the earlier paper (Palumbo et al., Prostate Cancer Prostatic Dis 2021) -0.64, p = 0.001 (this manuscript) vs. -0.44 p = 0.02 (Palumbo et al., Prostate Cancer Prostatic Dis 2021).</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>A few points which should be addressed:</p><p>– A supplementary table with the general characteristics of patients should be provided, e.g. in a supplementary table, for a better understanding of the study results, instead of referring to the previous publication.</p><p>– To make the manuscript more understandable (even for non-experts in the field) a brief mention to the mechanism of action of Degarelix should be given.</p><p>– Given the limited number of patients recruited for the study, power calculations should be provided.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Diane Harper (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>The authors addressed all the questions arising from the reviewers.</p><p>However, I still have a couple of remaining questions and suggestions. Firstly, while the authors' claim regarding FSH as a predictive marker for sarcopenic obesity seems convincing, associating it with cardiovascular complications appears far-fetched and is not supported by any evidence from this study.</p><p>The sentences in the discussion (lines 209-211, page 8) are unclear. This section serves as a summary of their findings and should be conveyed more clearly to the readers.</p><p>If I'm not mistaken, there was no correlation between FSH and any of the body composition parameters derived from DEXA. However, with Degarelix treatment, FSH became positively and negatively correlated with fat mass and ALMI/FBM, respectively.</p><p>The authors acknowledged that sex hormones were not measured in this protocol and the challenge of measuring them in the setting of Degarelix treatment. This limitation needs to be relayed to the readers in the discussion. I believe many readers will question the lack of data, given the intricate axis and the powerful impact of sex hormones on body composition.</p><p>Please change &quot;sexual hormones&quot; (line 215, page 9) to &quot;sex hormones&quot;.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92655.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions (for the authors):</p><p>Reviewer #1 (Recommendations for the authors):</p><p>If the authors can provide, the additional regression model might be helpful to understand the direct relationship between FSH and fat, especially sex hormones.</p></disp-quote><p>Regrettably, this cannot be accomplished because we do not have the circulating levels of estrogen and testosterone.</p><disp-quote content-type="editor-comment"><p>Please address the discrepancy of correlation coefficient (r) between FSH and ALBI in this manuscript and the earlier paper (Palumbo et al., Prostate Cancer Prostatic Dis 2021) -0.64, p = 0.001 (this manuscript) vs. -0.44 p = 0.02 (Palumbo et al., Prostate Cancer Prostatic Dis 2021).</p></disp-quote><p>We realized that 1 patient had a very high FSH value at 12 months in contrast to all other patients, we decided to remove this outlier value. We specified this in the new manuscript (page 6, lines 22-23) and in the Consort diagram.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>A few points which should be addressed:</p><p>– A supplementary table with the general characteristics of patients should be provided, e.g. in a supplementary table, for a better understanding of the study results, instead of referring to the previous publication.</p></disp-quote><p>As suggested by the reviewer, a table of patients characteristics was added in the supplementary materials.</p><disp-quote content-type="editor-comment"><p>– To make the manuscript more understandable (even for non-experts in the field) a brief mention to the mechanism of action of Degarelix should be given.</p></disp-quote><p>This was done in the new version: page 4, lines 7-8.</p><disp-quote content-type="editor-comment"><p>– Given the limited number of patients recruited for the study, power calculations should be provided.</p></disp-quote><p>This was done.</p><p>[Editors’ note: what follows is the authors’ response to the second round of review.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>The authors addressed all the questions arising from the reviewers.</p><p>However, I still have a couple of remaining questions and suggestions. Firstly, while the authors' claim regarding FSH as a predictive marker for sarcopenic obesity seems convincing, associating it with cardiovascular complications appears far-fetched and is not supported by any evidence from this study.</p></disp-quote><p>We changed the conclusions in both the abstract (page 2, lines 22, 23) and the manuscript (page 9, lines 23-25).</p><disp-quote content-type="editor-comment"><p>The sentences in the discussion (lines 209-211, page 8) are unclear. This section serves as a summary of their findings and should be conveyed more clearly to the readers.</p><p>If I'm not mistaken, there was no correlation between FSH and any of the body composition parameters derived from DEXA. However, with Degarelix treatment, FSH became positively and negatively correlated with fat mass and ALMI/FBM, respectively.</p></disp-quote><p>We reworded the above sentences (page 8, line 19-25; page 9, lines 1-2).</p><disp-quote content-type="editor-comment"><p>The authors acknowledged that sex hormones were not measured in this protocol and the challenge of measuring them in the setting of Degarelix treatment. This limitation needs to be relayed to the readers in the discussion. I believe many readers will question the lack of data, given the intricate axis and the powerful impact of sex hormones on body composition.</p></disp-quote><p>This limitation was more clearly aknowledged and discussed (page 9, lines 2-8).</p><disp-quote content-type="editor-comment"><p>Please change &quot;sexual hormones&quot; (line 215, page 9) to &quot;sex hormones&quot;.</p></disp-quote><p>Done (page 9, line 2).</p></body></sub-article></article>